Skip to main content
. 2022 Jul 11;13:942955. doi: 10.3389/fphar.2022.942955

FIGURE 3.

FIGURE 3

Systems analysis of the metabolomic alterations in each group. (A) Histogram of the relative expression levels of the biomarkers, (B) Metabolic pathway analysis associated with the pathogenesis of PD by MetaboAnalyst 5.0 (1. phenylalanine metabolism, 2. pentose and glucuronate interconversions, 3. arachidonic acid metabolism, 4. primary bile acid biosynthesis, 5. pantothenate and CoA biosynthesis, 6. tyrosine metabolism, 7. steroid hormone biosynthesis, 8. ascorbate and aldarate metabolism, 9. arginine and proline metabolism, and 10. purine metabolism), (C) Metabolic pathway analysis associated with the efficacy of DSS by MetaboAnalyst 5.0 (1. phenylalanine metabolism, 2. pentose and glucuronate interconversions, 3. arachidonic acid metabolism, 4. tyrosine metabolism, 5. steroid hormone biosynthesis, 6. pantothenate and CoA biosynthesis, 7. ascorbate and aldarate metabolism, and 8. purine metabolism).